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OBJECTIVES: To determine the effect of enrollment in a prescription drug plan on
use of controller medications in patients with persistent asthma. METHODS: The
study used a retrospective, cross sectional research design. The data source uti-
lized was the 2008 Medical Expenditure Panel Survey (MEPS), a nationally repre-
sentative sample of the non-institutionalized, civilian U.S. population. Analysis
was restricted to asthma patients who reported use of more than 3 canisters of
rescue inhalers in a three-month period. Controller medication use was self-re-
ported byMEPS respondants. Descriptive statisticswas used to describe the sample
and their controller medication use. A logistic regressionmodel was used to assess
the effect of prescription drug coverage based on the type of prescription drug plan
on the controller medication use while adjusting for age, gender, race, ethnicity,
income and perceived health status. All analyses were carried out using SASv.9.1.
RESULTS: Forty-two percent of respondents had prescription drug coverage while
67% reported use of controller medications. In the regression model, controller
medication use was found to be similar amongst patients with prescription drug
coverage and patients without coverage (68%, 66%, respectively). Patients with
prescription drug coverage were less likely to use controller medications than
those who did not have coverage, although this effect was not significant (OR 
0.53,CI:0.28-1.01). Patients with Medicare (OR 4.35, CI:1.61-11.75), Medicaid (OR
5.44, CI:2.23-13.24) or Veterans Affairs (OR  12.82, CI:3.21-51.16) prescription cov-
erageweremore likely to use controllermedicationswhen comparedwith patients
in other types of plans. Both pediatric patients (OR  5.51, CI:1.27-23.88) and pa-
tients with excellent perceived health status (OR 5.10, CI:2.04-12.76) had a higher
likelihood of using controller medications. CONCLUSIONS: Enrollment in a pre-
scription drug plan did not show a significant impact on use of controller medica-
tions. However, enrollment in Medicare, Medicaid or Veterans Affairs prescription
plans increased likelihood of controller medication use in this patient cohort.
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OBJECTIVES: The exposure to biofuel smoke is a risk factor for Chronic Obstructive
Pulmonary Disease –COPD- while using natural gas may be protective against it.
There is few evidence from Latin America on the relationship between use of
different types of fuels to cook and respiratory diseases. The present report is
aimed to assess differences in the prevalence of abnormalities to respiratory func-
tions between populations who used biomass fuel to cook against those using
cleaner sources of energy such as natural gas.METHODS: A cross-sectional popu-
lation based study was designed to evaluate the respiratory function, through spi-
rometry, in subjects cooking with biomass or natural gas. All patients were evalu-
ated by a general physician and a pulmonologist. We compared the prevalence of
spirometry abnormalities on those cooking with natural gas versus those cooking
with biomass fuel. A multivariable logistic regression was used to adjust differ-
ences by potential confounding factors. RESULTS: Overall 203 persons were stud-
ied. After adjusting by potential confounders there were a significant increase in
the prevalence of severe obstructive pattern (OR 5.50; 95% CI 1.17-25.79) in subjects
who cookwith biomass comparedwith natural gas users. Values of Forced Expired
Volume in one second (FEV1) and forced vital capacity (FVC) were lower among
those cooking with biomass. The differences in prevalence of respiratory mor-
bidity and symptoms were not statistically significant between both groups.
CONCLUSIONS: These findings suggest that replacing biomass fuel by natural gas
may be an important public health intervention in Colombia because it can reduce
the prevalence of abnormal patterns of pulmonary function.
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TRENDS IN ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS
FOR ADULTS IN THE UNITED STATES WITH NASOPHARYNGITIS, UPPER
RESPIRATORY TRACT INFECTIONS AND BRONCHITIS FROM 2006 TO 2008
Agrawal R, Shah J, Chopra P, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: The 2006 guidelines of the American Academy of Family Physicians
recommends to avoid prescribing of antibiotics to patients diagnosed with naso-
pharyngitis, acute upper respiratory tract infections (ARTI) or acute bronchitis.
Inappropriate prescribing of antibiotics to patients can lead to a rise in antibiotic-
resistant bacteria and subsequently increase the economic burden. The purpose of
this study was to determine the trends in the antibiotic prescribing rates for adults
diagnosed with nasopharyngitis, acute bronchitis or ARTIs in ambulatory care set-
tings in the United States after the 2006 guidelines. METHODS: This was a retro-
spective, cross-sectional analysis of the representative national survey of office
visits from theNational AmbulatoryMedical Care Survey for the years 2006 to 2008.
Adults18 years of age with a diagnosis of nasopharyngitis, ARTIs, or acute bron-
chitis were identified using International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes. Inappropriate antibiotic prescribing rates for the
three conditions were calculated separately and collectively. Descriptive analysis
was conducted to determine the utilization patterns by patient and physician char-
acteristics. Logistic regression was carried out to determine the trends in the anti-
biotic utilization. RESULTS: Analysis of multiyear data showed no statistically sig-
nificant trend (p-value  0.4622) in the antibiotic prescribing rates from 2006 to
2008. Approximately, 45.26 million office visits annually resulted in a primary di-
agnosis of nasopharyngitis, acuteURI, or acute bronchitis; of these visits, 1.5%, 44%,
and 61%, respectively, resulted in the prescribing of an antibiotic. Overall 47.26 % of
the study population was prescribed antibiotics. CONCLUSIONS: Antibiotic pre-
scription rate did not change significantly from 2006 to 2008. Antibiotics were pre-
scribed inappropriately in 47% of the adults diagnosedwith nasopharyngitis, ARTI,
or acute bronchitis. Concerted efforts are needed to improve antibiotic prescribing
practices for these conditions.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health issue and is a leading cause ofmorbidity andmortality in the United States1.
High frequency of exacerbations can lead to the further decline in lung function in
patients with moderate to severe COPD2. The objectives of this study was to gain a
better understanding of short-acting and long-acting beta-agonist use (SABA and
LABA, respectively) in the inpatient setting and describe beta-agonist effects on
total cost and length of stay (LOS).METHODS:Data from the Premier Perspective™
Database, a US national representative hospital database, was used to identify the
study population, which included adults 40 and olderwith an inpatient visit having
a principal discharge diagnosis code of COPD (ICD-9-CM 491.xx, 492.xx, 496) be-
tween January 1, 2006 and March 31, 2010. RESULTS: There were 165,055 individ-
uals with a primary diagnosis code during an inpatient visit. The mean age for
SABA only users was 68.9 years and 67.7 years for LABA only users (p0.0001). The
majority of the patients were female (56.9% SABA only, 56.9% LABA only, p 
0.9988) and white (72.3% SABA only, 66.4% LABA only, p 0.0001). The unadjusted
mean total cost for LABAuserswas $5,727 compared to $7,084 for SABA (p0.0001).
LOSwas not different between LABA and SABAusers:mean 5.5 and 6.7 (p 0.4786).
Inpatientmortality for both beta-agonist user groupswas below two percent (1.50%
SABA versus 0.34% LABA, p  0.0001). CONCLUSIONS: Descriptive analyses indi-
cate there are some differences among individuals with COPD using only LABA use
compared to SABA only use during an inpatient visit. Modeling outcomes adjusting
for potential differences such as demographics and concomitant drug use will be
performed to further describe this population.
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OBJECTIVES: This study describes concomitant asthmamedication use in patients
treated with omalizumab (Xolair®), a monoclonal antibody indicated for moderate
to severe persistent allergic asthma. METHODS: An analysis of health insurance
claims from three large databases was conducted: MarketScan (1996-2009), Medic-
aid (1997-2009), and Wellpoint (2002-2010). Patients 12 years old newly initiated
on omalizumab with 12months of continuous insurance coverage prior to the first
omalizumab dispensing (baseline period) and 2 asthma claims were included.
Concomitant asthmamedication usewas summarized in eightmedication classes:
ICS, LABA, leukotriene modifiers, mast cell stabilizers, anticholinergics, SABA,
methylxanthines, and oral corticosteroids, according to the 2007 National Asthma
Education and Prevention Program guidelines for managing asthma. RESULTS: A
total 6,038 patients were identified (Medicaid: 731; MarketScan: 3,521; Wellpoint:
1,786). Mean age (SD) was 38.8 (12.6), 44.6 (14.0), and 47.3 (15.6), and males repre-
sented 31%, 36%, and 39% in Medicaid, MarketScan, andWellpoint, respectively. A
high proportion of new omalizumab users have had an asthma-related ER visit
(Medicaid: 34%; MarketScan: 17%; Wellpoint: 16%) or hospitalization (Medicaid:
36%; MarketScan: 14%; Wellpoint: 21%) prior to initiating omalizumab. The major-
ity of patients (Medicaid: 96%; MarketScan: 89%; Wellpoint: 86%) received three
concomitant asthma medication classes or more during the baseline period. Con-
comitant ICS use was observed in 95%, 89%, and 86% of Medicaid, MarketScan, and
Wellpoint patients, respectively. Only 1% of omalizumab users in Medicaid and 3%
in MarketScan and Wellpoint received no other asthma medication prior to initi-
ating omalizumab. CONCLUSIONS: Based on this large observational study using
health insurance claims from three databases, a minority (1-3%) of omalizumab
users receive monotherapy treatment for asthma.
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OBJECTIVES: Compare retrospective initial maintenance treatment (IMT) analyses
results from propensity matched (PM) comparisons to multiple regression (MR)
results (adjusted for treatment, demographics and pre-initiation comorbidities and
utilization). TheMRand PMmethods are twowidely usedmethods in observational
comparative outcome studies of pharmaceutical treatments to adjust for baseline
differences in non-randomized treatment populations, but research on the extent
to which study findingsmay differ between themethods is sparse.METHODS:One
year post-initiation cost differences and utilization outcomes (odds ratios (OR)/
incidence rate ratios (IRR) for emergency department visit (ED), hospitalization, or
combination of either ED or hospitalization) for subjects diagnosed with chronic
obstructive pulmonary disease (COPD) were reviewed using data (January 2004
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through June 2009) for 32,338 patients aged40 years prescribed ipratropium (IPR)
(N10,617) or tiotropium (TIO) (N9,126) in comparison to fluticasone propionate/
salmeterol combination (FSC) (N12,595). Patients initiating with IPR (and sepa-
rately, TIO) werematched to patients initiating with FSC based on propensity to be
prescribed IPR (separately, TIO), considering demographics, comorbidities and uti-
lization characteristics assessed during 6 months before first IMT claim. RESULTS:
Percentage of each group propensitymatched to FSCwas 80.2%, IPR and 89.1%, TIO.
ORs (95% confidence intervals (CI)) for IPR vs. FSC were: ED - PM 1.86 (1.64-2.10), MR
1.81 (1.57-2.08); Hospitalization – PM 1.47 (1.27-1.70), MR 1.53 (1.35-1.75); ED/Hospi-
talization PM 1.67 (1.50-1.85), MR 1.72 (1.56-1.90). For TIO versus FSC, ORs (95% CI)
were: ED - PM 1.34 (1.14-1.47), MR 1.34 (1.17-1.54); Hospitalization – PM 1.10 (0.94-
1.28), MR 1.19 (1.04-1.37); ED/Hospitalization PM 1.21 (1.07, 1.36), MR 1.28 (1.15, 1.42).
IRRs reflected similar differences between themethods. Compared to FSC patients,
total COPD-related health care costs were higher for IPR (PM&MR, P0.01) and TIO
(PM P0.05, MR P0.01). CONCLUSIONS: The MR and PM methods of adjusting for
baseline differences between treatment populations produce similar results.
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THE CHARIOT STUDY: NOVEL DATA COLLECTION, VIEWING AND DYNAMIC
REPORTING MECHANISM
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OBJECTIVES: The significant burden of uncontrolled asthma can be translated into
substantial direct and indirect costs to the US health care system. The objectives of
the Characterization of Allergic Asthma: A Chart Review In Moderate-To-Severe
Disease To Assess Asthma Control, Allergies, Patient Outcomes And Treatment
Study (CHARIOT) study were to assess control of patients withmoderate-to-severe
asthma, examine the natural history of disease, practice patterns and resource
utilization in specialty community practices according to recent National Asthma
Education and Prevention Program guidelines by using a novel online approach to
gathering data and quickly demonstrating results. METHODS: This was a retro-
spective, multicenter, randomized study of 1009 patient charts in 60 US allergy and
pulmonology community practices. Assessment of patient control, the primary
endpoint, was achieved by analyzing data entered via internet-based or paper case
report forms (CRFs) Uncontrolled asthma was defined by occurrence of any of the
events in the recent 12 months of continuous follow-up: systemic corticosteroid
burst; frequent short-acting 2 agonist use; ER visit; asthma exacerbation (hospi-
talization and/or unscheduled visit; limitations on activities; decline in lung func-
tion to80% predicted FEV1 or PEF); daytime dyspnea; doubling of inhaled cortico-
steroid dose; or addition of another controller medication. RESULTS: A total of 114
sites were invited to participate in CHARIOT, with a 63% response rate leading to
site enrollment. Sixty investigator sites participated to completion and, after We-
bEx training, only 1 requested paper CRFs but later elected to use electronic forms.
Data was successfully collected and analyzed within a 3-month period. Of the 365
male and 644 female patients enrolled (mean 43.2 17.1 years), 81.9%were deemed
to be uncontrolled. CONCLUSIONS: Greater than 80% of asthma patients from
specialty practices were uncontrolled with regard to asthma symptoms. The novel
internet technology allowed for efficient data collection frommultiple sites within
a short time frame.
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MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING
DISCRETE EVENT SIMULATION (DES)
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OBJECTIVES: Smoking cessation models have typically evaluated the impact of a
single quit attempt on long term outcomes in smokers but smoking cessation is
characterized bymultiple quit attempts. A DES was developed to simulate lifetime
smoking patterns and the impact on smoking-related complications and costs.
This study evaluates the effect on predictions when modeling single versus mul-
tiple quit attempts.METHODS: Using data from trials, surveys, and the literature,
the DES simulates individuals’ lifetime smoking behaviors and their impact on
outcomes. The simulation assigns and reassigns the initial outcomes of each quit
attempt, time between quit attempts, relapses, and interventions used in each
attempt (varenicline, bupropion, nicotine replacement, behavioral modification,
unassisted). Comorbidities include myocardial infarction, stroke, COPD, and lung
cancer. Market survey data are used to assign the initial intervention for quit at-
tempts. Only direct costs (2010 $US) are considered. All outcomes are discounted at
3%/year. RESULTS:When analyses are restricted to a single quit attempt, mean life
expectancy in the population is 15.8 years, and QALYs 13.2; the lifetime costs of
treatment and smoking related comorbidities average $55,925. Allowing for multi-
ple quit attempts (average 7.6 attempts/smoker) increases the average time indi-
viduals spend abstinent by 8.8 years. Consequently, predicted life expectancy in-
creases by 1.1 years; QALYs by 0.9. Despite increased smoking intervention costs,
total lifetime costs fall by $3300/smoker. Analyses comparing initial varenicline
treatment to mixed initial treatments and allowing multiple versus single quit
attempts reduces varenicline-related predicted health gains and cost offsets, al-
though both groups have better outcomes with multiple quit attempts. The reduc-
tion is apparent because individuals initially on less effective treatments are able to
quit smoking in subsequent attempts. Nevertheless, varenicline is dominant or
highly cost-effective in both scenarios. CONCLUSIONS: Allowing multiple rather
than single quit attempts in simulating outcomes for smokers provides better in-
formation for decision making.
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QUESTIONNAIRE AS AN EXAMPLE
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OBJECTIVES: Providing participants with choices in how their data are collected
may lead to greater participation, less missing data, improved data quality, and in
some cases, decreased costs in data collection. To facilitate combining data from
multiple versions, the goals of this study were to provide recommended steps to
assess measurement comparability using a crossover study design and a case-
finding questionnaire, the Lung Function Questionnaire (LFQ), as an example.
METHODS: In the study, the LFQ was administered to participants via paper, Web,
interactive voice response system, and interview. A randomized crossover design
was used to gather data across themultiple administration types. In addition to the
LFQ, participants completed demographic and health questions, and a short ques-
tionnaire regarding their administration preference. Four recommended evalua-
tion steps are described and illustrated using data from the crossover study: 1)
comparisons of the item-level responses and agreement; 2) comparison of mean
scale scores; 3) classification of scores; and 4) questions designed to collect usability
and administration preference. RESULTS: In this example, item-level kappa statis-
tics between the paper and the alternate versions ranged from good to excellent,
intraclass correlation coefficients for mean scores were above 0.70, and the rate of
disagreement ranged from 2% to 14%. In addition, although participants had an
administration preference, they reported few difficulties with the versions they
were assigned. CONCLUSIONS: The steps described provide a guide for evaluating
whether to combine scores across administration versions to simplify analyses and
interpretation under a crossover design. The guide recommends the investigation
of item-level responses, summary scores, and participant usability/preference
when comparing versions. Each of these steps provides unique information to
support a comprehensive evaluation and informed decisions regarding whether to
combine data. Results of this particular study for each of the evaluation steps
supported the use of multiple modes of the LFQ.
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MEASURING COMORBIDITY: AN UPDATED CRITICAL REVIEW OF AVAILABLE
METHODS
Hermansson J1, Carlqvist P1, Kennedy K2, Pietri G2
1Heron AB, Stockholm, Sweden, 2HERON Evidence Development Ltd, Luton, UK
OBJECTIVES: Comorbidities are conditions or diseases besides the one of primary
interest. A comorbidity index condenses all the coexistent conditions to a single
score and comorbidity indexes have been extensively used to adjust analyses for
the impact of comorbidities. De Groot and colleagues published a literature review
in 2003 listing available indexes and reporting their validity.The objective of this
study was to review published methods to measure comorbidity and thereby pro-
vide an update of the publication by de Groot and colleagues.METHODS: A struc-
tured search, using as primary search terms comorbidity, multimorbidity, and co-
existing disease, was undertaken in Embase.com to identify studies published
since 2000 in which an index to measure comorbidity is described. For validity,
correlation coefficients, ratios, explained variance, and the area under the receiver
operating characteristic curve were used. Regression models predicting future
events that were significant or significantly improved after adding comorbidity as
a covariatewas considered to support validity. Parameters used to assess reliability
were among others correlation coefficients. RESULTS: Sixtyfour publications were
studied resulting in twentyfive different indexes, to measure comorbidity were
identified, compared to the thirteen identified by de Groot and colleagues (2003). In
line with previous findings, the Charlson Comorbidity Index (CCI) generated the
greatest number of studies and the most consistent results regarding validity and
reliability. CCI compiles the weighted mortality association of nineteen different
diseases with a number of adaptations for specific circumstances. CONCLUSIONS:
The main finding is that the CCI remains the most used and validated index, and
also a number of new comorbidity indexes have been identified in this study.
Assessment of comorbidity is an area of interest for both health economists and
epidemiologists and it seems to be receiving increased attention.
PRM2
MEASURING DRUG THERAPY GUIDELINES ON OUTCOMES: A TUTORIAL
Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To introduce amethod that combines the propensity score matching
and interrupted time-series models to measure drug therapy guidelines on
outcomes.METHODS: Propensity score matching is used to balance groups before
the trend is analyzed. The “kitchen sink” approach is used for propensity score
matching. Interrupted time-series models are applied over the matched sample.
The time-series model contains two predictor variables: the binary intervention
variable and an interval coding for time. This model controls for the confounding
influence of any underlying trend and ensures that any estimated change in the
mean level of the series after intervention is not simply due to the fact that the
series was already decreasing or increasing. RESULTS: To illustrate the model,
changes in the utilization of two hypothetical drugs were analyzed after issuance
of guidelines. Patients who used these two drugs were different at the baseline in
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